The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

April 13, 2020 • By Luis A. Marcos, MD, MPH, Saika Sharmeen, DO, Jaime Gonzalez, MD, Qingping Yao, MD, PhD, Bettina Fries, MD, & Jack Fuhrer, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The spike protein of SARS-CoV (SARS-S) induces ACE2 shedding via a process tightly linked with TNFα production.19 In an in vitro study, IL-6 and TNFα were up-regulated by the recombinant S protein of SARS-CoV, suggesting that TNF inhibitors and IL-6 antagonists may potentially reduce the inflammatory storm on SARS-CoV-2 and lung damage.20

You Might Also Like
  • The COVID-19 Infection Inflammation Equation
  • Don’t Forget the Host: COVID-19 Cytokine Storm
  • Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients
Explore This Issue
May 2020

In our cases, it is possible that pretreatment with etanercept for rheumatoid arthritis in our female patient could have resulted in a blunted IL-6 response indirectly, which may have contributed to her mild case of COVID-19. In support of this hypothesis is the patient’s normal plasma IL-6 level and a minimally elevated CRP, while other inflammatory markers remained within normal limits. Sha et al. demonstrated in a cohort of HIV patients pretreated with etanercept, TNFα and IL-6 levels were blunted after stimulation with IL-2.6 Our case also suggests the possibility that a TNFα inhibitor, such as etanercept, could minimize or abort the potential cytokine storm.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In contrast, COVID-19 infection in the husband was critical. The drug, secukinumab, he was receiving may have aggravated the viral infection. Secukinumab is a human IgG1κ monoclonal antibody that binds to the protein, IL-17A. In host defense, IL-17A has been shown to be mostly beneficial against infection caused by extracellular bacteria and fungi.21 The primary function of T helper (Th) 17 cells appears to be control of the gut microbiota, as well as the clearance of extracellular bacteria and fungi.22,23

IL-17A and IL-17 receptor signaling has been shown to play a protective role in host defenses against many bacterial and fungal pathogens, including Klebsiella pneumoniae, Mycoplasma pneumoniae, Candida albicans, Coccidioides posadasii, Histoplasma capsulatum and Blastomyces dermatitidis.24 However, IL-17A seems detrimental in viral infection, such as influenza, by promoting neutrophilic inflammation.25

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

It appears the clinical picture of COVID19 is characterized by a strong immune response in the lung parenchyma with mononuclear cells, mainly lymphocytes, more than the direct effect of viral replication.26

An autopsy study of these cases suggested that over-activation of T cells, manifest by an increase of Th17 and high cytotoxicity of CD8 T cells, accounts in part for the severe immune injury. Although the study suggested involvement of Th17, no Th17-associated cytokines were measured in our case. Th17 cells and IL-17 are involved in cytokine storm response. Both IL-1β and TNFα promote Th17 responses, leading to vascular permeability and leakage. Wu et al. proposed that inhibiting Th17 response may be beneficial.27

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions Tagged With: COVID-19Issue: May 2020

You Might Also Like:
  • The COVID-19 Infection Inflammation Equation
  • Don’t Forget the Host: COVID-19 Cytokine Storm
  • Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients
  • Unprecedented Cluster of Hyperinflammatory Shock in Kids in U.K., possibly Linked to COVID-19

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)